Overview

Gene Location [1]
13q12.3
Pathway
Receptor tyrosine kinase/growth factor signaling
Variant Type
Amplification
Gene
FLT1

FLT1 Amplification is present in 0.38% of AACR GENIE cases, with colorectal adenocarcinoma, breast carcinoma, bladder carcinoma, head and neck squamous cell carcinoma, and non-small cell lung carcinoma having the greatest prevalence [4].

Top Disease Cases with FLT1 Amplification

Significance of FLT1 Amplification in Diseases

Non-Small Cell Lung Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Esophageal Carcinoma +

Lymphoma +

Urothelial Carcinoma +

Pancreatic Carcinoma +

Cancer +

Gastric Carcinoma +

Gastrointestinal Stromal Tumor +

Hepatobiliary Neoplasm +

Lip And Oral Cavity Carcinoma +

Malignant Laryngeal Neoplasm +

Malignant Salivary Gland Neoplasm +

Malignant Solid Tumor +

Multiple Myeloma +

Nasal Cavity And Paranasal Sinus Carcinoma +

Nasopharyngeal Carcinoma +

Non-Hodgkin Lymphoma +

Oropharyngeal Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.